MDGL
Healthcare · Biotechnology
Performance
MDGL (MDGL) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
MDGL (MDGL) operates in the Biotechnology space within the Healthcare sector. With a market cap of $11.6B, it qualifies as a mid-cap company. Revenue is expanding quickly, but the company has yet to translate that growth into consistent profits — a common risk in high-growth early-stage businesses.
- Revenue grew 127% year-over-year — exceptional top-line expansion
- Current ratio of 3.5× — ample short-term liquidity
- Negative profit margin of -27.3% — company is currently unprofitable
- Negative ROE of -49.3% — shareholder equity is being eroded
- High debt-to-equity of 63.91× increases financial risk, especially with elevated interest rates
- No dividend history — total return depends entirely on price appreciation
Verdict
Avoid
Significant fundamental concerns outweigh positives. High risk at current levels.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
This stock does not pay dividends.
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Aug 5, 2026
50
days
EPS (TTM)
$-13.49
P/E (TTM)
—
Fwd P/E
40.5
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $501.74
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
N/A
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
3/10
43% score
Pays dividends
No dividend history found
Dividend consistency (5Y+)
Uninterrupted dividend payments for at least 5 years
ROE above 10%
-49.3%Return on equity — measures how efficiently capital is used
Positive profit margin
-27.3%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+126.8%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
63.91×Low financial leverage reduces risk of distress
Current ratio above 1
3.50×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$156M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
Healthcare
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Sector
Healthcare
Industry
Biotechnology
Location
West Conshohocken, United States
Employees
915